EP3634388A2 - Feste orale pharmazeutische zusammensetzungen von dabigatranetexilat - Google Patents

Feste orale pharmazeutische zusammensetzungen von dabigatranetexilat

Info

Publication number
EP3634388A2
EP3634388A2 EP18811675.0A EP18811675A EP3634388A2 EP 3634388 A2 EP3634388 A2 EP 3634388A2 EP 18811675 A EP18811675 A EP 18811675A EP 3634388 A2 EP3634388 A2 EP 3634388A2
Authority
EP
European Patent Office
Prior art keywords
weight
formulation
acid
capsule
pellets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18811675.0A
Other languages
English (en)
French (fr)
Inventor
Ali TÜRKYILMAZ
Arzu Palantöken
Ezel URAZ
Yildiz GÜLKOK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64559741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3634388(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority claimed from PCT/TR2018/050221 external-priority patent/WO2019004980A2/en
Publication of EP3634388A2 publication Critical patent/EP3634388A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • the present invention relates to solid oral pharmaceutical compositions, comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and at least one organic acid in a dosage unit form comprising of a first capsule and a second capsule, the second capsule which is located within the first capsule.
  • Dabigatran is a potent, reversible, univalent direct thrombin inhibitor. Dabigatran was first disclosed in WO98/37075, which claimed compounds with a thrombin-inhibiting effect and the effect of prolonging the thrombin time, under the name 1 -methyl-2-[N-[4-(N-n- hexyloxycarbonylamidino) phenyl] aminomethyl] benzimidazol-5-ylcarboxylic acid-N-(2- pyridyl)-N-(2 ethoxycarbonylethyl)amides.
  • Dabigatran etexilate a novel direct thrombin inhibitor, is a prodrug of dabigatran and is a non-peptide thrombin inhibitor.
  • the structural formula is:
  • Dabigatran is currently available as dabigatran etexilate mesylate, under the trade name Pradaxa from Boehringer Ingelheim is used for the reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
  • the solubility of dabigatran etexilate in water is 1 .8 mg/mL and dependent on the pH value.
  • EP1658056B1 suggests a tablet formulation containing dabigatran etexilate and an organic acid with a solubility in water of > 1g / 250 ml at 20°C.
  • WO2015145462A1 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising a first component in the form of tablet comprising dabigatran and a second component in the form of capsule comprising organic acid.
  • the main object of the present invention is to provide solid oral pharmaceutical compositions, comprising dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and at least one organic acid in a unit dosage form with good stability and effective dissolution profile.
  • Another object of the present invention is to obtain a stable dabigatran etexilate formulation with high bioavailability.
  • Another object of the present invention is to provide an easy and cost-effective process for the preparation of the said pharmaceutical composition.
  • said pharmaceutical composition comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof and at least one organic acid, wherein the composition is in a dosage unit form comprising a first capsule and a second capsule which is located within the first capsule.
  • the term "unit dosage form” refers to nested capsule technology which is comprising a first capsule and a second capsule, the second capsule being located within the body of the first capsule.
  • the first capsule comprises a first formulation which may be a direct thrombin inhibitor or an organic acid.
  • the second capsule comprises a second formulation which may be a direct thrombin inhibitor or an organic acid.
  • dabigatran etexilate free base refers to dabigatran etexilate which is free from other forms of the active moiety, especially acid addition salts.
  • the first capsule is comprising a first formulation held between the first and second capsule, and a second formulation held in the second capsule.
  • compatible formulations refers to the first and the second formulation which are comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or an organic acid.
  • the first formulation and the second formulation are in the form of mini tablets or granules or pellets or powder or beads or capsules or mixtures thereof.
  • the first formulation is comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or an organic acid.
  • the second formulation is comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or an organic acid.
  • the pharmaceutical composition in a dosage unit form comprising a first capsule and a second capsule which is located within the first capsule, wherein the first capsule comprising a first formulation held between the first and second capsule and comprising a second formulation held in the second capsule, and wherein the first formulation or the second formulation comprising a direct thrombin inhibitor in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof or at least one organic acid.
  • the direct thrombin inhibitor is dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof.
  • Suitable organic acid is comprising at least one carboxylic group. It may include but not limited to citric acid, tartaric acid, gallic acid, orotic acid, p-coumaric acid, hippuric acid, ferulic acid, vanillic acid, fumaric acid, maleic acid, succinic acid, malic acid, glutamic acid, aspartic acid, oxalic acid, lactic acid, formic acid, acetic acid, propionic acid, caproic acid, benzoic acid, carbonic acid, adipic acid or mixtures thereof.
  • the organic acid is citric acid or tartaric acid or mixtures thereof.
  • the organic acid has important role in high bioavailability and solubility of dabigatran etexilate.
  • use of high amount of organic acid may cause incompatibilities in the patient or can limit the amount of drug used in the pharmaceutical preparation due to their intrinsic properties. That reasons should be taken in consideration when determining the amount of the direct thrombin inhibitor and the organic acid in the pharmaceutical composition.
  • the weight ratio of the direct thrombin inhibitor to the organic acid is between 0.6 and 8.0, preferably the ratio is between 1 .0 and 5.0.
  • the weight ratio of the dabigatran etexilate to the citric acid is between 0.6 and 8.0, preferably the ratio is between 1 .0 and 5.0.
  • the weight ratio of the dabigatran etexilate to the tartaric acid is between 0.6 and 8.0, preferably the ratio is between 1 .0 and 5.0.
  • the said composition comprises at least one pharmaceutically acceptable excipient selected from fillers, disintegrants, diluents, dispersing agents, binders, lubricants, glidants, plasticizers, preservatives, sweeteners, flavorings, melting components, coloring agents, solvents, or mixtures thereof.
  • Suitable fillers may include but not limited to lactose, sugar, starches, modified starches, mannitol, calcium sulfate, xylitol, or mixtures thereof.
  • Suitable disintegrants may include but not limited to cross-linked polyvinil pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, polyacrylate potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • cross-linked polyvinil pyrrolidone crospovidone
  • povidone cross-linked carboxymethyl cellulose
  • croscarmellose sodium cross-linked carboxymethyl cellulose
  • low-substituted hydroxypropyl cellulose pregelatinized
  • Suitable diluents may include but not limited to microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • Suitable dispersing agents may include but not limited to calcium silicate, magnesium aluminum silicate or mixtures thereof.
  • Suitable binders may include but not limited to polyvinylpyrrolidone, carnauba wax, pullulan, glyceryl behenate, polycarbophil, polyvinyl acetate and its copolymers, cellulose acetate phthalate, hydroxypropyl starch, sugars, tragacanth gum, cetostearyl alcohol, acacia mucilage, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium, ethyl cellulose, microcrystalline cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, carrageenan, guar gum, polymethacrylates
  • Suitable lubricants may include but not limited to magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyceryl palmito stearate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • Suitable glidants may include but not limited to colloidal silicon dioxide, talc, aluminium silicate, silica or mixtures thereof.
  • Suitable plasticizers may include but not limited to polyethylene glycols of different molecular weights, propylene glycol or mixtures thereof.
  • Suitable preservatives may comprise but not limited to methyl paraben and propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene and butylated hydroxyanisole or mixtures thereof.
  • Suitable sweeteners may include but not limited to aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose and sugar alcohols such as mannitol, sorbitol, xylitol, erythritol or mixtures thereof.
  • Suitable flavorings may include but not limited to menthol, peppermint, cinnamon, chocolate, vanillin and fruit essences such as cherry, orange, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries etc. or mixtures thereof.
  • Suitable melting components are selected from gelucire (stearyl macrogolglyceride), poloxamer (polyoxyethylene-polyoxypropylene block copolymer), polyethylene glycol, povidone, soluplus, cationic methacrylate, copovidone, methacrylic acid copolymers, cellulose acetate phthalate, acetylated monoglyceride, butil pthalybutyl glycolate, dibutyl tartrate, diethyl phthalate, dimethly phthalate, ethyl phthalylethly glycolate, glycerin, propylene glycol, triacetin, triacetin citrate, tripropionin or mixtures thereof.
  • Suitable coloring agents may include but not limited to ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine), iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • D&C Drug & Cosmetic
  • Suitable solvents may include but not limited to ethyl alcohol, 2-propanol or mixtures thereof.
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1 .0 - 30.0% by weight of binder
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1 .0 - 30.0% by weight of binder
  • the pharmaceutical compositi comprises the first formulation and the second formulation wherein;
  • the first formulation comprising - 10.0 - 50.0% by weight of organic acid pellets or coated (isolated) organic acid pellets or powder mixture containing organic acid, and
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • citric acid or tartaric acid pellets or coated (isolated) citric acid or tartaric acid pellets or powder mixture containing citric acid or tartaric acid and
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • citric acid or tartaric acid pellets or coated (isolated) citric acid or tartaric acid pellets or powder mixture containing citric acid or tartaric acid and
  • the second formulation comprising - 30.0 - 80.0% by weight of dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 10.0 - 50.0% by weight of microcrystalline cellulose
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • compositions of the present invention may be prepared by a process comprising the following steps: a. Preparing the first formulation in the form of mini tablets or granules or pellets or powder or beads or capsules or mixtures thereof;
  • Fig. 1 shows Table-1 containing Examples 1 -6.
  • Fig. 2 shows Table-2 containing Examples 1 -6.
  • granulating represents a process to provide granular product consisting of particles each having almost same size and shape, from a starting material in the form of powder, melt or aqueous solution.
  • granules refers to agglomerates of particles.
  • compositions of the present invention may be prepared using wet-granulating processes in which a powder is added with a binder and a solvent then granulated, dry- granulating processes such as slugging or compaction and direct compression, or melt- granulating processes in which a powder is mixed with a heat-melting binder and then heat-granulated.
  • These granulating processes may be combined with various granulating processes such as agitating granulation method used with machines such as planetary mixers and screw mixers, high shear granulation method used with machines such as Henschel mixers and super mixers, extrusion granulation method used with machines such as cylindrical, rotary granulator, screw-extruding granulator and pellet-mill granulator, or other processes like, tumbling-granulation method, fluidized-bed granulation method, compression granulation method, crushing granulation method, and spray dry granulation method.
  • the foregoing granulation processes may be used alone and no limitation in usage.
  • the particles may then be milled to achieve the desired particle size.
  • suitable processes for milling the granules include hammer milling, ball milling, fluid-energy milling, roller milling, cutting milling, or other milling processes known in the art.
  • pellets refers to small particles with approximately uniform shapes and sizes produced by an extrusion process.
  • a "small particle” refers to a particle of which diameter, length, height, and width is at most 10 mm (e.g., at most 2, 3, 4, 5, 6, 7, 8, or 9 mm).
  • spherical pellet refers to beads, beadlets, spherical particles, spheroids, or the like that are of round or about round in shape and are generally made by an extrusion and spheronization process.
  • mini tablet refers to small tablets with a diameter equal to or less than 4 mm that are typically filled into a capsule or further compressed into larger tablets. Thickness of this mini tablets equal to or less than 3 mm. The mini tablets have round shape and smooth surface to ease coating process.
  • step (b) Granulating the blend of step (a); c. Drying or cooling the granules obtained in step (b);
  • step (c) optionally adding at least one pharmaceutically acceptable excipient to the granules obtained in step (c) and mixing;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or second formulation comprising the following steps:
  • step (a) Granulating the blend of step (a) to form organic acid granules or extruding or spheronizing the blend of step (a) to form organic acid pellets;
  • step (b) or step (c) Filling the organic acid granules or pellets obtained in step (b) or step (c) into the first capsule or the second capsule.
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets; iii. Optionally coating the organic pellets with an isolation solution;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps: a. Preparing the first formulation comprising
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets; iii. Optionally coating the organic pellets with an isolation solution;
  • step (iv.) Optionally adding lubricant to the granules obtained in step (iii) and mixing; c. Filling the second formulation into the second capsule and;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Granulating the blend of step (i) with water;
  • step (i) Extruding or spheronizing the blend of step (i) to form citric acid pellets or tartaric acid pellets;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Extruding or spheronizing the blend of step (i) to form citric acid pellets or tartaric acid pellets;
  • step (i) Granulating the blend of step (i) with water;
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or the second formulation comprising the following steps:
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process for the first or the second formulation comprising the following steps:
  • the organic acid pellets or the organic acid granules are coated with an isolation solution.
  • the isolation solution is formed of a polymeric or a non-polymeric pharmaceutically acceptable agent or any combination thereof.
  • the raw material of the capsule is hydroxypropyl methylcellulose (HPMC) or gelatin which can be alkali-treated gelatin, acid-treated gelatin, or chemically modified gelatin.
  • HPMC hydroxypropyl methylcellulose
  • gelatin which can be alkali-treated gelatin, acid-treated gelatin, or chemically modified gelatin.
  • the capsule material may further include agar, starch, alginic acid, guar gum, plasticizer and mixtures thereof.
  • HPMC based capsules has retardant effects on the rate of dissolution compared to gelatin based capsules. Gelatin based capsules can be more preferable than HPMC based capsules when using acid in the pharmaceutical composition.
  • the capsule filled with the organic acid pellets, or the coated organic acid pellets, or the powder mixture containing organic acid is made of gelatin or HPMC, preferably gelatin.
  • the capsule filled with comprising the citric acid pellets, or the coated citric acid pellets, or the powder mixture containing citric acid is made of gelatin or HPMC, preferably gelatin.
  • the capsule filled with the tartaric acid pellets, or the coated tartaric acid pellets, or the powder mixture containing tartaric acid is made of gelatin or HPMC, preferably gelatin.
  • the capsule filled with dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof is made of gelatin or HPMC.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Dabigatran Etexilate Granules Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Example 3
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinize starch are sieved and blended. Magnesium stearate is added and mixed 1 -2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed. Preparation of Nested Capsules
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • Formula 2 HPMC and triethyl citrate are added to purified water and mixed. Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Citric acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • isolation solution which is selected from Formula 1 to 3.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinize starch are sieved and blended. Magnesium stearate is added and mixed 1 -2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed. Preparation of Nested Capsules
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule.
  • coated citric acid pellets or citric acid pellets or powder mixture containing citric acid instead of coated citric acid pellets or citric acid pellets or powder mixture containing citric acid, we can put coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid.
  • Example 5 Example 5:
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Dabigatran Etexilate Granules Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Example 7
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinize starch are sieved and blended. Magnesium stearate is added and mixed 1 -2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed. Preparation of Nested Capsules
  • Coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Citric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Citric acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Citric acid, lactose spray dried, colloidal silicone dioxide and pregelatinize starch are sieved and blended. Magnesium stearate is added and mixed 1 -2 more minutes.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated citric acid pellets or citric acid pellets or powder mixture containing citric acid are filled into the first capsule.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • isolation solution which is selected from Formula 1 to 3.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed.
  • Coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Tartaric acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • isolation solution which is selected from Formula 1 to 3.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed. This mixture is granulated with water. The granules are dried at 50°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the first capsule.
  • Production method 2 :
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed.
  • the powder mixture is granulated with water and dried in an oven at 50°C. Magnesium stearate is added and mixed 1 -2 more minutes.
  • the powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the first capsule.
  • Dabigatran etexilate, microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are mixed. Some of the magnesium stearate is added to the blend and mixed. The mixture is compressed by roller compaction. The compressed mixture (granules) is sieved. Remaining magnesium is added to the sieved granules and mixed. Preparation of Nested Capsules
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated tartaric acid pellets or tartaric acid pellets or powder mixture containing tartaric acid are filled into the first capsule.
  • the present invention provides other solutions by using cyclodextrin or polyvinylpyrrolidone (PVP) or polyethylene glycol (PEG) or mixture thereof for increasing solubility of dabigatran etexilate in these pharmaceutical compositions.
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) Adding lubricant to the granules obtained in step (vi) and mixing;
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets; iii. Optionally coating the organic pellets with an isolation solution;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • the first formulation comprising - 30.0 - 80.0% by weight of dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) Adding magnesium stearate to the granules obtained in step (vi) and mixing; b. Preparing the second formulation comprising
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • binder - 1 .0 - 30.0% by weight of binder
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (i) Extruding or spheronizing the blend of step (i) to form organic acid pellets; iii. Optionally coating the organic pellets with an isolation solution;
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) Adding lubricant to the granules obtained in step (vi) and mixing;
  • the pharmaceutical composition comprises the first formulation and the second formulation wherein;
  • citric acid or tartaric acid pellets or coated (isolated) citric acid or tartaric acid pellets or powder mixture containing citric acid or tartaric acid and
  • dabigatran etexilate in the form the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates, hydrates or esters thereof;
  • microcrystalline cellulose - 5.0 - 50.0% by weight of microcrystalline cellulose
  • colloidal silicon dioxide - 0.1 - 3.0% by weight of colloidal silicon dioxide
  • magnesium stearate - 0.1 - 5.0% by weight of magnesium stearate
  • Another embodiment of the present invention provides a method of preparing of the pharmaceutical composition, wherein the process comprising the following steps:
  • step (v) Drying the granules obtained in step (v) and sieving;
  • step (vi) Adding magnesium stearate to the granules obtained in step (vi) and mixing.
  • c Filling the second formulation into the second capsule and;
  • Example 11 Inserting the second capsule into the first capsule and subsequently filling the first formulation into the first capsule.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and sucrose are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol.
  • Cyclodextrin or PVP or PEG is suspended with water.
  • Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol at 30-35°C.
  • Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol.
  • Cyclodextrin or PVP or PEG is suspended with water.
  • Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol at 30-35°C.
  • Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved.
  • Magnesium stearate is added and mixed 1 -2 more minutes. The powder mixture is compressed into mini tablets.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate in the form of mini tablets are filled into the first capsule.
  • Dabigatran etexilate, Cyclodextrin or PVP or PEG, Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide, croscarmellose sodium and half of magnesium stearate are sieved and mixed.
  • the mixture is compressed by roller compaction.
  • the compressed mixture (granules) is sieved.
  • Remaining magnesium stearate is added to the sieved granules and mixed.
  • Coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the second capsule.
  • the second capsule is inserted into the first capsule and dabigatran etexilate granules are filled into the first capsule.
  • Organic acid and microcrystalline cellulose are blended and this blend is added solution of hydroxypropyl cellulose in isopropyl alcohol to get a wet mass. This wet mass is extruded, spheronized, dried and screened to give pellets.
  • HPMC and triethyl citrate are added to purified water and mixed.
  • Talc is added to the obtained mixture and mixed.
  • HPMC HPMC is added to purified water and mixed in homogenisator.
  • Talc and PEG 6000 are added to the obtained mixture and mixed in homogenisator.
  • Organic acid pellets are coated with isolation solution which is selected from Formula 1 to 3.
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol.
  • Cyclodextrin or PVP or PEG is suspended with water.
  • Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol at 30-35°C.
  • Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved. Magnesium stearate is added to the dried granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Production method 2 :
  • Dabigatran etexilate is suspended with ethyl alcohol or 2-propanol.
  • Cyclodextrin or PVP or PEG is suspended with water.
  • Suspension of cyclodextrin or PVP or PEG is added to the dabigatran etexilate suspended with ethyl alcohol or 2-propanol at 30-35°C.
  • Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide and croscarmellose sodium are sieved and mixed and subsequently mixed with the blend of dabigatran etexilate and granulated. The granules are dried at 55°C and sieved.
  • Magnesium stearate is added and mixed 1 -2 more minutes. The powder mixture is compressed into mini tablets.
  • Dabigatran etexilate in the form of mini tablets are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • Dabigatran etexilate, Cyclodextrin or PVP or PEG, Microcrystalline cellulose, hydroxypropyl methyl cellulose, colloidal silicon dioxide, croscarmellose sodium and half of magnesium stearate are sieved and mixed.
  • the mixture is compressed by roller compaction.
  • the compressed mixture (granules) is sieved.
  • Remaining magnesium stearate is added to the sieved granules and mixed.
  • Dabigatran etexilate granules are filled into the second capsule.
  • the second capsule is inserted into the first capsule and coated organic acid pellets or organic acid pellets or powder mixture containing organic acid are filled into the first capsule.
  • organic acid is selected from a group comprising citric acid, tartaric acid, gallic acid, orotic acid, p-coumaric acid, hippuric acid, ferulic acid, vanillic acid, fumaric acid, maleic acid, succinic acid, malic acid, glutamic acid, aspartic acid, oxalic acid, lactic acid, formic acid, acetic acid, propionic acid, caproic acid, benzoic acid, carbonic acid, adipic acid or mixtures thereof.
  • organic acid is citric acid or tartaric acid or mixture thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18811675.0A 2017-05-10 2018-05-10 Feste orale pharmazeutische zusammensetzungen von dabigatranetexilat Withdrawn EP3634388A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2017/06848A TR201706848A2 (tr) 2017-05-10 2017-05-10 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR2018/06309A TR201806309A2 (tr) 2017-05-10 2018-05-04 Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
PCT/TR2018/050221 WO2019004980A2 (en) 2017-05-10 2018-05-10 SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE

Publications (1)

Publication Number Publication Date
EP3634388A2 true EP3634388A2 (de) 2020-04-15

Family

ID=64559741

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18811674.3A Withdrawn EP3621599A2 (de) 2017-05-10 2018-05-10 Feste orale pharmazeutische zusammensetzungen von dabigatranetexilat
EP18811675.0A Withdrawn EP3634388A2 (de) 2017-05-10 2018-05-10 Feste orale pharmazeutische zusammensetzungen von dabigatranetexilat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18811674.3A Withdrawn EP3621599A2 (de) 2017-05-10 2018-05-10 Feste orale pharmazeutische zusammensetzungen von dabigatranetexilat

Country Status (8)

Country Link
EP (2) EP3621599A2 (de)
AU (1) AU2018293361B2 (de)
BR (1) BR112019023781A2 (de)
CO (1) CO2019013649A2 (de)
EA (1) EA201992644A1 (de)
NZ (1) NZ759901A (de)
TR (2) TR201706848A2 (de)
WO (1) WO2019004979A2 (de)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
PL2588090T3 (pl) * 2010-07-01 2017-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole
HUE056194T2 (hu) * 2012-02-21 2022-01-28 Towa Pharmaceutical Europe S L Dabigatrán-etexilát orális gyógyszerészeti készítményei
EP2740471B1 (de) 2012-12-07 2015-05-27 Hexal AG Orale pharmazeutische Zusammensetzung mit Dabigatranetexilat
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
IN2014MU01042A (de) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
EP2929884A1 (de) * 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische kombinationen aus dabigatran und h2-rezeptor-antagonisten
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
WO2016142821A2 (en) * 2015-03-09 2016-09-15 Alphamed Formulations Pvt. Ltd Compositions containing a thrombin inhibitor
IN2015CH01145A (de) * 2015-03-09 2016-09-16

Also Published As

Publication number Publication date
TR201706848A2 (tr) 2018-11-21
EP3621599A2 (de) 2020-03-18
AU2018293361A1 (en) 2020-01-02
TR201806309A2 (tr) 2018-11-21
EA201992644A1 (ru) 2020-04-07
WO2019004979A3 (en) 2019-04-11
CO2019013649A2 (es) 2020-05-15
AU2018293361B2 (en) 2021-09-16
WO2019004979A2 (en) 2019-01-03
NZ759901A (en) 2021-12-24
BR112019023781A2 (pt) 2020-06-02

Similar Documents

Publication Publication Date Title
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
US20170000799A1 (en) Oral pharmaceutical composition
US20170333424A1 (en) Amorphous Vortioxetine Hydrobromide
JP2012184267A (ja) 安定性の向上した固形製剤およびその製造方法
KR102082775B1 (ko) 수용해도 및 생체이용율이 개선된 조성물
JP2013532651A (ja) シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
WO2015145462A1 (en) Pharmaceutical compositions of dabigatran
WO2023195955A1 (en) A film coated tablet comprising selexi̇pag and its preparation process
EP2012754B1 (de) Orale pharmazeutische formulierung mit schneller freisetzung für esomeprazol
JPWO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
WO2023195957A1 (en) A film coated tablet comprising selexi̇pag processed with wet granulation
TWI871668B (zh) 醫藥調配物
WO2019004980A2 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
KR102707060B1 (ko) 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
EP3787624A2 (de) Kapsel-in-kapsel-zusammensetzungen von dabigatran-etexilat
JP5818219B2 (ja) ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
WO2016139683A2 (en) Pharmaceutical compositions of lurasidone and process for preparing the same
JP6737060B2 (ja) イルベサルタンを含有する医薬組成物の製造方法
WO2021153525A1 (ja) エソメプラゾール経口製剤およびその製造方法
AU2018293361B2 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
JP2021080191A (ja) ニロチニブを有効成分とする医薬錠剤及びその製造方法
EA016579B1 (ru) Твердый фармацевтический препарат, содержащий гидрохлорид ирбесартана, и способ его изготовления
EP3342401A1 (de) Zweischichtige tablettenformulierungen von dabigatranetexilat
JP2021167306A (ja) 崩壊性粒子の製造方法
WO2025164725A1 (ja) ジヒドロピリジノン誘導体を含有する医薬組成物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220107

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220518